Organogenesis Holdings announced it received a innovative technology contract with Vizient for its portfolio of advanced wound care and surgical and sports medicine products.
Organogenesis Holdings (NASDAQ:ORGO) announced it received a innovative technology contract with Vizient for its portfolio of advanced wound care and surgical and sports medicine products.
As quoted in the press release:
The contract for the Organogenesis product portfolio was based on a recommendation from hospital experts who serve on one of Vizient’s member-led councils. The portfolio includes PuraPly Antimicrobial (PuraPly AM); Apligraf, the only product to have received FDA approval for treating both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs); Dermagraft, which is FDA approved for treating DFUs; as well as FiberOS, NuCel, NuShield, OCMP and ReNu.
“We are honored that Vizient, the largest health care performance improvement company in the country, with more than 3,100 hospital and health system members, has awarded Organogenesis this Innovative Technology contract for our comprehensive and differentiated advanced wound care and surgical and sports medicine portfolios,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “We are delighted to have received this contract and look forward to offering Vizient members across the county our innovative products as part of their move to value-based care.”